Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UC Irvine UCLA
Dates
study started
completion around

Description

Summary

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

Official Title

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Keywords

Advanced Solid Tumors Cancer, Cancer, Advanced Solid Tumor, Neoplasm, Neoplasms, Nivolumab, Erlotinib Hydrochloride, Osimertinib, Monoclonal Antibodies, Telisotuzumab vedotin, Erlotinib, Monotherapy Telisotuzumab vedotin (21-day dosing cycles), Monotherapy Telisotuzumab vedotin(28-day dosing cycles), Telisotuzumab vedotin plus Erlotinib, Telisotuzumab vedotin plus Nivolumab, Telisotuzumab vedotin plus Osimertinib

Eligibility

Locations

  • University of California, Los Angeles /ID# 148295
    Los Angeles California 90095 United States
  • UC Irvine /ID# 165107
    Orange California 92868 United States
  • University of California, Davis Comprehensive Cancer Center /ID# 129805
    Sacramento California 95817 United States
  • City of Hope /ID# 153759
    Duarte California 91010 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT02099058
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 237 people participating
Last Updated